8-K: XOMA Announces Merger Closing and Preferred Stock Redemption

XOMA Royalty Corporation expects its acquisition by Ligand Pharmaceuticals to close on July 14, 2026, and has initiated the full redemption of its outstanding preferred stock.

Summary

• The acquisition of XOMA Royalty Corporation by Ligand Pharmaceuticals is expected to close on or about July 14, 2026.
• The company has issued notices for the full redemption of all outstanding 8.625% Series A Cumulative Perpetual Preferred Stock and 8.375% Series B Cumulative Perpetual Preferred Stock.
• Redemption of all preferred shares will occur on July 14, 2026, at a price of $25.00 per share/depositary share, plus accrued and unpaid dividends.
• A record date for the distribution of Contingent Value Rights (CVRs) to common stockholders has been set for July 13, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for shareholders as it provides a clear timeline for the merger completion and ensures the orderly redemption of preferred securities.

Positives

• The pending merger provides a clear path to liquidity for shareholders.
• Preferred stockholders will receive full redemption value ($25.00 per share) plus accrued dividends.
• Common stockholders are entitled to receive CVRs as additional merger consideration, providing potential upside from the Janssen Litigation.

Negatives

• Preferred stock will cease to be listed on The Nasdaq Stock Market following the redemption.
• Dividends on preferred stock will cease to accrue after the July 14, 2026, redemption date.

Risks

• The merger remains subject to the satisfaction or waiver of remaining closing conditions.
• There is a risk that the acquisition does not close in the anticipated timeframe or at all.
• Failure to obtain necessary regulatory approvals or stockholder approval could derail the transaction.
• The potential for competing offers to emerge.

Future Outlook

The company expects the acquisition by Ligand Pharmaceuticals to close on or about July 14, 2026, subject to customary closing conditions.

Management Comments

• Management has confirmed the expected closing date for the merger and the subsequent redemption of all outstanding preferred securities.

Industry Context

StockSavvy.ai notes that this transaction is consistent with the ongoing consolidation trend in the pharmaceutical royalty and intellectual property sector, where larger entities like Ligand are acquiring specialized royalty portfolios to bolster their long-term revenue streams.

Comparison to Industry Standards

• The redemption of preferred stock at par value plus accrued dividends is standard practice in M&A transactions involving publicly traded preferred equity.
• The use of CVRs as additional consideration is a common mechanism in biotech M&A to bridge valuation gaps regarding pending litigation or clinical trial outcomes.

Corporate Governance

Legal Proceedings

• The CVRs are related to the Janssen Litigation as described in the Merger Agreement.

Stakeholder Impact

• Shareholders: Expected to receive merger consideration and CVRs.
• Preferred Stockholders: Will receive full redemption value plus accrued dividends.
• Employees: Potential for organizational changes following the integration with Ligand.

Next Steps

• Stockholders to vote on the proposed acquisition.
• Payment of preferred dividends on or about July 15, 2026.
• Completion of the merger and redemption of preferred stock on July 14, 2026.

Key Dates

Recommendation

With the merger closing date set and the acquisition price likely already reflected in the current market price, investors should hold until the transaction is finalized.

Keywords

XOMA, Ligand Pharmaceuticals, Merger, Preferred Stock Redemption, Contingent Value Rights, Biotech, Royalty